Piperazine ,1-(2-methylphenyl)-Hydrochloride

Some type of inverse agonists, cannabinoid receptor 1 (CB1) has been shown to be an anti-obesity appetite suppressant drug candidate. However, the first generation of CB1 inverse agonist rimonabant (SR141716A) is indicated taranabant otenabant and are centrally acting, with a high degree of psychiatric side effects. Therefore, the discovery of CB1 inverse agonists can be separated with a chemical backbone of these promising for the development of peripheral CB1 inverse agonist effective with fewer side effects. We generated a new CB1 inverse agonists (4- (bis (4-fluorophenyl) methyl) piperazin-1-yl) (cyclohexyl) methanone (LDK1229), from the class of the analogs of benzhydryl piperazine. This compound selectively binds to more than CB1 receptor cannabinoid type 2, with a Ki of 220 nM. CB1 comparable binding was also observed analogues of 1- [bis (4-fluorophenyl) methyl] -4-cinnamyl piperazine (LDK1203) and 1- [bis (4-fluorophenyl) methyl] -4-piperazine tosyl (LDK1222) represented by the substitution on the piperazine ring, where the piperazine and LDK1203 LDK1222 are each substituted with an alkyl shift and a tosyl group. LDK1229 has a comparable efficacy SR141716A antagonize the baseline activity of the G protein coupling CB1, as indicated by a reduction of guanosine 5'-O- (3-thio) triphosphate binding. In accordance with the inverse agonist behavior, increased CB1 location of the cell surface after treatment with LDK1229 was also observed. Although reception and mutation analysis showed that LDK1229 shapes similar interactions with the case of receptor SR141716A the benzhydryl piperazine skeleton structurally inverse agonists of first generation CB1 receptors. It offers new opportunities for the development of novel CB1 inverse agonists by optimizing the molecular properties, such as the polar surface and hydrophilic properties to reduce SR141716A observed with the core activity.

α-L-lyxo-Hexopyranoside, methyl 3-amino-2,3,6-trideoxy-, hydrochloride

Product name: α-L-lyxo-Hexopyranoside, methyl 3-amino-2,3,6-trideoxy-, hydrochloride 
CAS no.: 32385-06-1 
Molecular Formula: C7H16ClNO3 
Molecular Weight: 197.66 
Product description: Than the star like sugar intermediates.
From:http://www.chemicalspharm.com/New-Products/%CE%B1-L-lyxo-Hexopyranoside-methyl-3-amino-236-trideoxy--hydrochloride/

Carbamic acid

About Produts:

Product name: Carbamic acid, [2-(4-aminophenyl)ethyl][(2R)-2-hydroxy-2-phenylethyl]-, 1,1-dimethylethyl ester 
CAS no.: 223673-36-7

Molecular Formula: C21H28N2O3 
Molecular Weight: 356.45862

Product description: Mira peron intermediate.

Would like to ask specific details, please click here Email:sales@chemicalspharm.com

CN-23 gaseous hydrocarbon steam reforming catalyst

Product name: CN-23 gaseous hydrocarbon steam reforming catalyst 
Category: Reforming Catalyst for Honeycomb-shaped & Tube-shell Heat Exchanged Reformer

Description: With nickel as the active component, alumina as the carrier, and rare earth oxide as the co-catalyst, CN-23 gaseous hydrocarbon steam reforming catalyst applies to the heat exchanged reformer in synthetic ammonia plant.
 

New advances in brain sensor - wireless, soluble

Researchers from abroad have developed a wireless brain sensor that can monitor intracranial pressure and temperature, but also can be absorbed by the body, to reduce surgical removal of routine monitoring of equipment. The researchers pointed out that the implant as such can be used to monitor patients with traumatic brain injury, but they think we can build a similar sensor can be absorbed for monitoring activities in the organ systems throughout the body, research published in the International the magazine Nature.

Researchers Rory KJ Murphy said, in recent years, electronic devices and the rapid development of medical devices, is currently the biggest obstacle we face is that the implant will often induce specific immune responses, which the patient or the existence of certain risks; but these devices for patients benefit is its will slowly dissolve over time, the use of such sensors can also reduce the solubility surgeon surgical removal of the equipment required, which greatly reduces the risk of infection and complications of the patients body.

In the United States there are about 50,000 people each year die from trauma, such as traumatic brain injury, when a patient enters the hospital for treatment, the doctor must be conducted in patients with intracranial pressure measurement, because of the increased intracranial pressure often lead to further brain damage and the current through the brain scans and clinical characteristics, doctors can not reliably determine the patient's intracranial pressure. The researchers pointed out, but the most commonly used devices are based on 1980s technology developed, these devices larger, use more cumbersome, but also in the intensive care unit with its need to connect an external monitor to use. The new sensor developed by the researchers of this article, which is mainly composed of a polylactic acid polyglycolic acid (PLGA) and a silicone composition, but it can transmit accurate pressure, temperature, and other parameters. With the design and development of advanced materials and equipment, researchers might develop a more accurate implant electronically, and thereby facilitate the clinician operation.
Bolise Co., Ltd.

NG108-15

Retinitis pigmentosa (RP) is a group of inherited disorders in which abnormalities of the photoreceptors (rods and cones) or the retinal pigment epithelium (RPE) of the retina lead to progressive visual loss. Stakeholders first experience defective dark adaptation or "night blindness," followed by a narrowing of the peripheral visual field and possibly a loss of central vision late in the course of the disease.

P3-X63-Ag8

Alzheimer's disease is associated with a dense accumulation of proteins in amyloid plaques in the brain containing fragments of amyloid-beta as the main component. If the development of amyloid plaques is responsible for neurodegeneration in Alzheimer's disease, a reduction in the formation of beta-amyloid and the progress of development may prevent the symptoms of the disease. Fragments of beta amyloid proteolytic processing of the amyloid precursor protein (APP) derivatives in neurons and the subsequent release of fragments in the extracellular space. APP is cleaved in the ER at residue 17 encoded by the activity of the alpha-secretase protease ADAM-10 and TACE. Beta-secretase activity, as recently identified BACE cleaves the N-terminus of beta-amyloid fragment. Gamma secretase cuts in the APP transmembrane domain at amino acids 40 and 42, the release of residues amyloid beta fragments 1-40 / 42 and short articles as ASP3 (residues 17-40 / 42), alpha secretase cleavage requires. The gamma-secretase activity requires the transmembrane protein presenilin-1, which is divided into an N-terminal fragment and C-terminal which are both required for the gamma-secretase activity. Mutations in presenilin-1 are genetically associated with familial forms of Alzheimer's disease, even supporting the role of APP processing to develop the disease. Inhibition of beta or gamma secretase can provide a mechanism to treat this disease. Other mechanisms altering the degradation of beta-amyloid and use of vaccines against amyloid beta aggregates to contain to remove.